Vitamin D: Proteases, protease inhibitors and cancer

Cell Cycle

Volumn 9, Issue 1, 2010, Pages 32-37

  Álvarez Díaz, Silvia ^a   Larriba, María Jesús ^a   López Otín, Carlos ^b   Muñoz, Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Cancer; Cystatins; Protease inhibitors; Proteases; Proteasome; Ubiquitin; Vitamin D

Indexed keywords

BORTEZOMIB; CALCITRIOL; CYSTATIN; CYSTATIN D; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR; SEOCALCITOL; SERINE PROTEINASE; UNCLASSIFIED DRUG; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; DRUG MECHANISM; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PROGNOSIS; PROTEIN DEGRADATION; REVIEW;

EID: 74549186671     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.1.10266     Document Type: Review

References (44)

1. López-Otín C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008; 283:30433-7.
2. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7:800-8.
3. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997; 378:141-50.
4. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med 2009; 30:191-296.
5. Kaiser P, Huang L. Global approaches to understanding ubiquitination. Genome Biol 2005; 6:233.
6. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68:1015-68.
7. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4:876-90.
8. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6:764-75.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74.
10. McCawley LJ, Crawford HC, King LE Jr, Mudgett J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004; 64:6965-72.
11. Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35:252-7.
12. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700.
13. Ordóñez-Morán P, Larriba MJ, Pendás-Franco N, Aguilera O, González-Sancho JM, Muñoz A. Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci 2005; 10:2723-49.
14. Eelen G, Gysemans C, Verlinden L, Vanoirbeek E, De Clercq P, Van Haver D, et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr Med Chem 2007; 14:1893-910.
15. Ordóñez-Morán P, Muñoz A. Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 2009; 8:1675-80.
16. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003; 4:46-56.
17. Ordóñez-Morán P, Larriba MJ, Pálmer HG, Valero RA, Barbáchano A, Dunach M, et al. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype and Wnt pathway in colon cancer cells. J Cell Biol 2008; 183:697-710.
18. Carlberg C, Seuter S. A genomic perspective on vitamin D signaling. Anticancer Res 2009; 29:3485-93.
19. Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH. Regulation of gene expression by 1á,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol Endocrinol 2001; 15:1127-39.
20. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 2002; 16:1243-56.
21. Savli H, Aalto Y, Nagy B, Knuutila S, Pakkala S. Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a cDNA array study. Br J Haematol 2002; 118:1065-70.
22. Pálmer HG, Sánchez-Carbayo M, Ordóñez- Morán P, Larriba MJ, Cordón-Cardó C, Muñoz A. Genetic signatures of differentiation induced by 1?,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res 2003; 63:7799-806.
23. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 2003; 80:49-62.
24. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004; 59:243-51.
25. Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, Bai W. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J Biol Chem 2005; 280:35458-68.
26. Alvarez-Díaz S, Valle N, García JM, Peña C, Freije JM, Quesada V, et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest 2009; 119:2343-58.
27. Balbín M, Hall A, Grubb A, Mason RW, López-Otín C, Abrahamson M. Structural and functional characterization of two allelic variants of human cystatin D sharing a characteristic inhibition spectrum against mammalian cysteine proteinases. J Biol Chem 1994; 269:23156-62.
28. Freije JP, Abrahamson M, Olafsson I, Velasco G, Grubb A, López-Otín C. Structure and expression of the gene encoding cystatin D, a novel human cysteine proteinase inhibitor. J Biol Chem 1991; 266:20538-43.
29. Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, et al. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res 2004; 64:6957-64.
30. Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, Sotiropoulou G, et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 2004; 23:2206-15.
31. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer 2009.
32. Takahashi H, Ibe M, Honma M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. 1,25-dihydroxyvitamin D(3) increases human cystatin A expression by inhibiting the Raf-1/MEK1/ERK signaling pathway of keratinocytes. Arch Dermatol Res 2003; 295:80-7.
33. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996; 58:367-76.
34. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001; 153:999-1010.
35. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNFalpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000; 106:1127-37.
36. Guenette RS, Mooibroek M, Wong K, Wong P, Tenniswood M. Cathepsin B, a cysteine protease implicated in metastatic progression, is also expressed during regression of the rat prostate and mammary glands. Eur J Biochem 1994; 226:311-21.
37. Byrne B, Welsh J. Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells. J Steroid Biochem Mol Biol 2007; 103:703-7.
38. Mathiasen IS, Hansen CM, Foghsgaard L, Jaattela M. Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves upregulation of the TNF receptor 1 and cathepsin B. Int J Cancer 2001; 93:224-31.
39. Koli K, Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues downregulate cell invasionassociated proteases in cultured malignant cells. Cell Growth Differ 2000; 11:221-9.
40. Bao BY, Yeh SD, Lee YF. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006; 27:32-42.
41. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224:1-22.
42. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249:61-79.
43. Vlachostergios PJ, Patrikidou A, Daliani DD, Papandreou CN. The Ubiquitin-Proteasome System in cancer, a major player in DNA Repair. Part 1: Posttranslational regulation. J Cell Mol Med 2009.
44. Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 2009; 8:1688-97.